BR0215193A - Formulações de azitromicina diretamente compressìveis - Google Patents

Formulações de azitromicina diretamente compressìveis

Info

Publication number
BR0215193A
BR0215193A BR0215193-6A BR0215193A BR0215193A BR 0215193 A BR0215193 A BR 0215193A BR 0215193 A BR0215193 A BR 0215193A BR 0215193 A BR0215193 A BR 0215193A
Authority
BR
Brazil
Prior art keywords
azithromycin
tablet
mga
pharmaceutically acceptable
acceptable excipient
Prior art date
Application number
BR0215193-6A
Other languages
English (en)
Inventor
Brendn John Murphy
Steven William Collier
Ernest Shing Quan
Barbara Alice Johnson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0215193A publication Critical patent/BR0215193A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçõES DE AZITROMICINA DIRETAMENTE COMPRESSìVEIS". A presente invenção refere-se a uma mistura seca, usada para formar comprimidos de azitromicina por compressão direta, compreendendo azitromicina não-diidrato e pelo menos um excipiente farmaceuticamente aceitável. Esta invenção refere-se também a um comprimido de azitromicina compreendendo azitromicina não-diidratada e pelo menos um excipiente farmaceuticamente aceitável. Preferencialmente, o comprimido de azitromicina é formado por compressão direta da mistura seca, da presente invenção, para formar o referido comprimido de azitromicina. Preferencialmente, o comprimido de azitromicina, da presente invenção, contém uma dosagem de 250 mgA, 500 mgA e 600 mgA. Esta invenção refere-se ainda a um comprimido de azitromicina que é produzido formando uma mistura seca de uma azitromicina não granulada de forma A e pelo menos um excipiente farmaceuticamente aceitável. O comprimido de azitromicina é então formado por compressão direta da mistura seca.
BR0215193-6A 2001-12-21 2002-12-09 Formulações de azitromicina diretamente compressìveis BR0215193A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34348001P 2001-12-21 2001-12-21
PCT/IB2002/005222 WO2003053416A1 (en) 2001-12-21 2002-12-09 Directly compressible formulations of azithromycin

Publications (1)

Publication Number Publication Date
BR0215193A true BR0215193A (pt) 2004-11-16

Family

ID=23346277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215193-6A BR0215193A (pt) 2001-12-21 2002-12-09 Formulações de azitromicina diretamente compressìveis

Country Status (21)

Country Link
US (4) US20030165563A1 (pt)
EP (1) EP1455758A1 (pt)
JP (1) JP2005513099A (pt)
KR (1) KR100632339B1 (pt)
CN (1) CN1668282A (pt)
AR (1) AR037930A1 (pt)
AU (1) AU2002348884A1 (pt)
BR (1) BR0215193A (pt)
CA (1) CA2469246A1 (pt)
IL (1) IL161996A0 (pt)
MX (1) MXPA04005105A (pt)
NO (1) NO20043110L (pt)
NZ (1) NZ532707A (pt)
PA (1) PA8562201A1 (pt)
PE (1) PE20030591A1 (pt)
PL (1) PL371259A1 (pt)
PY (1) PY0231025A (pt)
RU (1) RU2277914C2 (pt)
TW (1) TW200301138A (pt)
WO (1) WO2003053416A1 (pt)
ZA (1) ZA200403486B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
IL161996A0 (en) * 2001-12-21 2005-11-20 Pfizer Prod Inc Directly compressible formulations of azithromycin
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0211620D0 (en) * 2002-05-21 2002-07-03 Bioprogress Technology Ltd Powder compaction and enrobing
US20030228370A1 (en) * 2002-06-11 2003-12-11 Michel Serpelloni Orodispersible solid pharmaceutical form
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
WO2005002592A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Stable oral compositions of azithromycin monohydrate
WO2005004919A2 (en) * 2003-07-02 2005-01-20 Eurand, Inc. Extended release systems for macrolide antibiotics
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
CA2547239A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
JP2007513139A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
JP2007513145A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 医薬用多微粒子の製造方法
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
WO2006067577A2 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Stable non-dihydrate azithromycin oral suspensions
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
EP2124963A4 (en) * 2006-12-20 2010-03-17 Mylan Pharmaceuticals Ulc COMPOSITION WITH A BISPHOSPHONIC ACID IN COMBINATION WITH VITAMIN D
RU2336073C1 (ru) * 2007-01-10 2008-10-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат тилорон
JP5623275B2 (ja) * 2007-07-31 2014-11-12 カーギル インコーポレイテッド 直接打錠可能なデキストロース
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
BRPI0822359A2 (pt) * 2008-03-18 2015-07-14 Aleksander Vladimirovich Dikovskiy Composição farmacêutica de antibióticos e prebióticos para prevenir e tratar disbiose durante terapia antibacteriana
EP2266582B1 (en) * 2008-03-18 2015-04-29 Dikovskiy, Aleksander Vladimirovich Pharmaceutical composition for preventing dysbiosis associated with enteral administration of antibiotics
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
KR20150092385A (ko) 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
US20150242975A1 (en) 2014-02-24 2015-08-27 Mindojo Ltd. Self-construction of content in adaptive e-learning datagraph structures
US20160145548A1 (en) * 2014-11-20 2016-05-26 The Procter & Gamble Company Cleaning composition refill for an automatic dishwasher dispensing device
CN105193753A (zh) * 2015-10-30 2015-12-30 成都通德药业有限公司 一种阿奇霉素分散片的制备方法
CN110633487B (zh) * 2019-07-03 2023-03-14 北京中医药大学 直接压片的片剂处方的设计方法
CN111467362B (zh) * 2020-05-09 2021-07-06 北京四环制药有限公司 一种阿奇霉素药用组合物及其制备方法和其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RO107257B1 (ro) * 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
TW271400B (pt) * 1992-07-30 1996-03-01 Pfizer
CA2189001A1 (en) * 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
EP0758244B2 (en) * 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
IL119866A (en) 1996-12-19 1999-12-31 Unipharm Ltd Antibiotic tablet
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
ATE353014T1 (de) * 1997-09-10 2007-02-15 Merial Ltd Verwendung von 9a-azaliden als antimikrobielle mittel für tiere
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
JP2002531409A (ja) * 1998-11-30 2002-09-24 テバ ファーマシューティカル インダストリーズ リミティド アジスロマイシンのエタノール付加物、その製造方法、及びその医薬製剤
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
CA2485433C (en) * 1999-11-26 2008-01-29 Astur Pharma S.A. Preparation of non-crystalline and crystalline dihydrate forms of azithromycin
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
AU2001214115A1 (en) 2000-08-01 2002-02-13 Habil F. Khorakiwala Process for the preparation of anhydrous azithromycin
IL158591A0 (en) * 2001-05-22 2004-05-12 Pfizer Prod Inc Crystal forms of azithromycin
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US6764997B2 (en) * 2001-10-18 2004-07-20 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions
EP1455757A2 (en) * 2001-12-21 2004-09-15 Pfizer Products Inc. Methods for wet granulating azithromycin
IL161996A0 (en) * 2001-12-21 2005-11-20 Pfizer Prod Inc Directly compressible formulations of azithromycin
BR0307331A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formulações granuladas a seco de azitromicina

Also Published As

Publication number Publication date
US20060024363A1 (en) 2006-02-02
US20050287209A1 (en) 2005-12-29
PA8562201A1 (es) 2003-07-28
WO2003053416A1 (en) 2003-07-03
ZA200403486B (en) 2006-05-31
PY0231025A (es) 2004-07-01
RU2277914C2 (ru) 2006-06-20
IL161996A0 (en) 2005-11-20
CN1668282A (zh) 2005-09-14
MXPA04005105A (es) 2004-08-19
PL371259A1 (pl) 2005-06-13
US7070811B2 (en) 2006-07-04
JP2005513099A (ja) 2005-05-12
KR20040066175A (ko) 2004-07-23
CA2469246A1 (en) 2003-07-03
AU2002348884A1 (en) 2003-07-09
US20030165563A1 (en) 2003-09-04
US20060024364A1 (en) 2006-02-02
AR037930A1 (es) 2004-12-22
NZ532707A (en) 2006-07-28
RU2004118709A (ru) 2005-04-20
NO20043110L (no) 2004-07-20
TW200301138A (en) 2003-07-01
EP1455758A1 (en) 2004-09-15
PE20030591A1 (es) 2003-07-12
KR100632339B1 (ko) 2006-10-12

Similar Documents

Publication Publication Date Title
PY0231025A (es) Formulaciones de azitromicina directamente compresibles
TW200633730A (en) Oral disintegrating dosage forms
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
BR0213288A (pt) Etilcelulose altamente compressìvel para formação de comprimidos
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
TW200716208A (en) Modified and immediate release memantine bead formulation
HN2001000012A (es) Tratamiento de la enfermedad neurodegenerativa
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
TR200002207T1 (tr) Slekoksib bileşikleri.
ES2187822T3 (es) Comprimidos de disgregacion rapida.
BR0015188A (pt) Composições farmacêuticas
BR0211972A (pt) Composição oftálmica
BR0005938A (pt) Composição de dosagem oral com libaraçãoprolongada
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
BR0204001A (pt) Forma de dosagem oral sólida de simeticona
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
BR0215148A (pt) Composições farmacêuticas de agonista parcial 5ht4
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
GB2361186B (en) Formulation for the prevention of cardiovascular disease
GB0012362D0 (en) Chemical compounds
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 9/20; A61K 31/7052; A61P 31/00

Ipc: A61K 9/20 (2011.01), A61K 31/7052 (2011.01), A61P

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.